David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post on X:
“Interesting read on cancer drug development strategies. Here example is mobocertinib, known affectionately as ‘Mobo’, withdrawn from accelerated approval due to a negative Phase 3 trial. Overly ambitious?”
“Withdrawn NSCLC Drug: Was Ambitious Phase 3 Trial Design to Blame?”
Author: Neil Osterweil
More posts featuring David Gandara.